Observational studyJCO clinical cancer informatics2025
Consumer Wearable Device Measures of Gait Cadence and Activity Fragmentation as Predictors of Survival Among Patients Undergoing Chemotherapy.
Observational study in JCO clinical cancer informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinician Perspectives on Integrating Mobile Sensor Data Into Cancer Care: Mixed Methods Study.JMIR cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeConsumer wearable devices provide new opportunities for measuring patterns of objective daily physical activity throughout cancer treatment. In addition to capturing step counts, these devices can also measure gait cadence and activity fragmentation, two metrics that may reflect functional capacity. The goal of the current study was to examine whether step count, gait cadence, and activity fragmentation predicted overall survival in patients with solid tumors.
methodsWe enrolled patients (N = 213) receiving outpatient chemotherapy for any solid tumor into an observational cohort study. Patients wore a consumer wearable device to measure continuous physical activity patterns for up to 90 days and were followed for a median of 2.53 years, during which 42% of the sample died. Univariable and multivariable Cox proportional hazards regression analyses were used to evaluate associations between wearable device physical function metrics and survival.
resultsIn univariable analyses, higher step count (hazard ratio (HR), 0.87;
conclusionActivity fragmentation and gait cadence metrics derived from consumer wearable devices were associated with overall survival in patients receiving chemotherapy for any solid tumor. These associations remained statistically significant after adjustment for covariates, including clinician-rated performance status and patient-reported physical function. These findings suggest that wearable devices may capture important prognostic information about physical function independent of what clinicians and patients perceive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.